Pfizer Launches Three Biosimilars Targeting Roche’s Blockbuster Biologics: Zirabev, Ruxience, and Trazimera Now Available in the U.S.

January 29, 2020 /BioonBIOON/ --Pfizer(Pfizer) recently announced the launch of three new products in the U.S. marketBiosimilars, respectively: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr), and Trazimera (trastuzumab-qyyp). These three biosimilars target Roche’s three flagship biologic agents: Avastin, Rituxan, and Herceptin. Pfizer stated that theseBiosimilarsSupply will be provided at the lowest Wholesale Acquisition Cost (WAC) of currently marketed products (bevacizumab, rituximab, and trastuzumab), offering significant discounts compared to branded drugs.

Pfizer North AmericaTumorAngela Lukin, President of the Learning Region, stated: “We are proud to expand our industry-leading portfolio by launching these three drugs.”BiosimilarsProduct Portfolio, which will bring significant cost savings to the U.S. healthcare system while increasing access to critical therapies. We look forward to collaborating with payers and providers for patients with certain cancers andAutoimmunity“Provide these essential medications to patients with the disease.”

Pfizer’s Launched and/or UpcomingTumorMonoclonal AntibodiesBiosimilarsIncluding:

——Zirabev: Launched in the United States on December 31, 2019, with a Wholesale Acquisition Cost (WAC) of $61.34 per 10 mg, representing a 23% discount compared to the WAC of the brand-name drug Avastin. This medication is indicated for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent, or metastatic cervical cancer.

Pfizer plans to expand the label for Zirabev in January 2021 to include the treatment of epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, subject to regulatory approval.

——Ruxience: Launched in the US on January 23, 2020, with a Wholesale Acquisition Cost (WAC) of $71.68 per 10 mg, representing a 24% discount compared to the WAC of the brand-name drug Rituxan. This medication is indicated for the treatment of adult patients with non-Hodgkin lymphoma (NHL) and chronic lymphocyticLeukemia(CLL), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). This drug is the first approved for the treatment of GPA and MPA.Biosimilars。

——Trazimera: Launched in the US on February 15, 2020, with a Wholesale Acquisition Cost (WAC) of $80.74 per 10 mg, representing a 22% discount compared to the WAC of the brand-name drug Herceptin. This drug is indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressingBreast Cancerand HER2-overexpressing positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

According toFDABiosimilar Database: 26 in Total to DateBiosimilarsObtainedFDAApproved, with nine targeting Roche’s three flagship biologics: Avastin (2), Herceptin (5), and MabThera (2).

Deputy Director of Clinical Research, Stanford Comprehensive Cancer Institute; Breast, Stanford Women's Cancer CenterTumorDr. Mark Pegram, Program Director, commented, “The launch of these three new biosimilars in the United States is highly significant, providing additional treatment options for patients with nine types of cancer. Biosimilars can play an important role in the care of cancer patients. TheseBiosimilars"Highly similar to the reference product, it will improve patient access to treatment."

Over the past decade,BiosimilarsIt has always been a key catalyst for transformation in the global healthcare industry, with the potential to create a more sustainable healthcare system. Pfizer is proud to stand at the forefront of this critical area of healthcare.

Pfizer owns30 years of experience in biologics manufacturing, over 10 years of global market experience in biosimilars, and up to 8 approved products in the United StatesBiosimilarsThe product's industry-leading position.(Bioon.com)

Original Source:Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts